​In Alzheimer’s disease, cognitive disturbances are associated with and paralleled by a decrease in cerebral glucose metabolism.

Likewise, hypo-metabolism in the brain is found in pre-diabetic and T2D patients. While waiting for specific treatments to conquer underlying vascular, TAU and beta-amyloid pathologies in dementia, manipulating neuro-energetics seems to be a means of improving neuronal function or even preventing neurodegeneration.

We therefore test the acute effect of ketone bodies on cognition and perfusion with the long-term aim of providing protective and possibly alleviating drugs based on ketone bodies to diabetes patients at high risk for cognitive disturbances.​